Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of AVP-786 for agitation in Alzheimer's disease dementia
2020-000798-26Phase 3Active
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Sep 2020
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of deudextromethorphan and quinidine in Alzheimer's disease (AD) (2 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Change from baseline to end of efficacy period in Cohen-Mansfield Agitation Inventory total score. Started Sep 2020; status: active.
02
Drugs
deudextromethorphanquinidine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2020-000798-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000798-26.